174 related articles for article (PubMed ID: 35602894)
1. The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma.
Ding Y; Yao J; Wen M; Liu X; Huang J; Zhang M; Zhang Y; Lv Y; Xie Z; Zuo J
PeerJ; 2022; 10():e13473. PubMed ID: 35602894
[TBL] [Abstract][Full Text] [Related]
2. Personalized circulating tumor DNA in patients with hepatocellular carcinoma: a pilot study.
Pommergaard HC; Yde CW; Ahlborn LB; Andersen CL; Henriksen TV; Hasselby JP; Rostved AA; Sørensen CL; Rohrberg KS; Nielsen FC; Rasmussen A
Mol Biol Rep; 2022 Feb; 49(2):1609-1616. PubMed ID: 34811635
[TBL] [Abstract][Full Text] [Related]
3. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R
Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.
Ikeda S; Lim JS; Kurzrock R
Mol Cancer Ther; 2018 May; 17(5):1114-1122. PubMed ID: 29483209
[TBL] [Abstract][Full Text] [Related]
5. Bioinformatics Analysis of Candidate Genes and Pathways Related to Hepatocellular Carcinoma in China: A Study Based on Public Databases.
Zhang P; Feng J; Wu X; Chu W; Zhang Y; Li P
Pathol Oncol Res; 2021; 27():588532. PubMed ID: 34257537
[No Abstract] [Full Text] [Related]
6. Detection of MET gene somatic mutations in hepatocellular carcinoma of Egyptian patients using next-generation sequencing.
Ahmed E; El-Dien A N; Sabet S; Khalifa M; El Hamshary M
Biomarkers; 2023 Jun; 28(4):379-386. PubMed ID: 36825430
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma.
Wu X; Li J; Gassa A; Buchner D; Alakus H; Dong Q; Ren N; Liu M; Odenthal M; Stippel D; Bruns C; Zhao Y; Wahba R
Int J Biol Sci; 2020; 16(9):1551-1562. PubMed ID: 32226301
[TBL] [Abstract][Full Text] [Related]
8. [The role of circulating tumor DNA in the diagnosis and prognosis of hepatocellular carcinoma].
Fan ZH; Ren F
Zhonghua Gan Zang Bing Za Zhi; 2022 Dec; 30(12):1382-1386. PubMed ID: 36891725
[TBL] [Abstract][Full Text] [Related]
9. Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma.
von Felden J; Craig AJ; Garcia-Lezana T; Labgaa I; Haber PK; D'Avola D; Asgharpour A; Dieterich D; Bonaccorso A; Torres-Martin M; Sia D; Sung MW; Tabrizian P; Schwartz M; Llovet JM; Villanueva A
Oncogene; 2021 Jan; 40(1):140-151. PubMed ID: 33097857
[TBL] [Abstract][Full Text] [Related]
10. Analysis of potential key genes in very early hepatocellular carcinoma.
Wu M; Liu Z; Li X; Zhang A; Lin D; Li N
World J Surg Oncol; 2019 May; 17(1):77. PubMed ID: 31043166
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment.
Sogbe M; Bilbao I; Marchese FP; Zazpe J; De Vito A; Pozuelo M; D'Avola D; Iñarrairaegui M; Berasain C; Arechederra M; Argemi J; Sangro B
Clin Mol Hepatol; 2024 Apr; 30(2):177-190. PubMed ID: 38163441
[TBL] [Abstract][Full Text] [Related]
12. Current status of ctDNA in precision oncology for hepatocellular carcinoma.
Li Y; Zheng Y; Wu L; Li J; Ji J; Yu Q; Dai W; Feng J; Wu J; Guo C
J Exp Clin Cancer Res; 2021 Apr; 40(1):140. PubMed ID: 33902698
[TBL] [Abstract][Full Text] [Related]
13. Identifying hepatocellular carcinoma-related hub genes by bioinformatics analysis and CYP2C8 is a potential prognostic biomarker.
Li C; Zhou D; Jiang X; Liu M; Tang H; Mei Z
Gene; 2019 May; 698():9-18. PubMed ID: 30825595
[TBL] [Abstract][Full Text] [Related]
14. Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib.
Fujii Y; Ono A; Hayes CN; Aikata H; Yamauchi M; Uchikawa S; Kodama K; Teraoka Y; Fujino H; Nakahara T; Murakami E; Miki D; Okamoto W; Kawaoka T; Tsuge M; Imamura M; Chayama K
J Exp Clin Cancer Res; 2021 Jun; 40(1):215. PubMed ID: 34174931
[TBL] [Abstract][Full Text] [Related]
15. Prospects and challenges of circulating tumor DNA in precision medicine of hepatocellular carcinoma.
Weng J; Atyah M; Zhou C; Ren N
Clin Exp Med; 2020 Aug; 20(3):329-337. PubMed ID: 32239299
[TBL] [Abstract][Full Text] [Related]
16. Screening Hub Genes as Prognostic Biomarkers of Hepatocellular Carcinoma by Bioinformatics Analysis.
Zhou Z; Li Y; Hao H; Wang Y; Zhou Z; Wang Z; Chu X
Cell Transplant; 2019 Dec; 28(1_suppl):76S-86S. PubMed ID: 31822116
[TBL] [Abstract][Full Text] [Related]
17. [Screening core genes and cyclin B2 as a potential diagnosis, treatment and prognostic biomarker of hepatocellular carcinoma based on bioinformatics analysis].
Yang SY; Ren H; Li CF; Tang H
Zhonghua Gan Zang Bing Za Zhi; 2020 Sep; 28(9):773-783. PubMed ID: 33053978
[No Abstract] [Full Text] [Related]
18. Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma.
Cai Z; Chen G; Zeng Y; Dong X; Li Z; Huang Y; Xin F; Qiu L; Xu H; Zhang W; Su X; Liu X; Liu J
Clin Cancer Res; 2019 Sep; 25(17):5284-5294. PubMed ID: 31217202
[TBL] [Abstract][Full Text] [Related]
19. MLH1 single-nucleotide variant in circulating tumor DNA predicts overall survival of patients with hepatocellular carcinoma.
Kim SS; Eun JW; Choi JH; Woo HG; Cho HJ; Ahn HR; Suh CW; Baek GO; Cho SW; Cheong JY
Sci Rep; 2020 Oct; 10(1):17862. PubMed ID: 33082400
[TBL] [Abstract][Full Text] [Related]
20. Identification of potential miRNA-mRNA regulatory network contributing to pathogenesis of HBV-related HCC.
Lou W; Liu J; Ding B; Chen D; Xu L; Ding J; Jiang D; Zhou L; Zheng S; Fan W
J Transl Med; 2019 Jan; 17(1):7. PubMed ID: 30602391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]